More than 400,000 patient courses of both the monoclonal therapies from Eli Lilly and Regeneron have been allocated to states, and more than 250,000 have been delivered—but very little of what has been distributed is actually being used.

 

More than 400,000 patient courses of both the monoclonal therapies from Eli Lilly and Regeneron have been allocated to states, and more than 250,000 have been delivered—but very little of what has been distributed is actually being used. https://t.co/WALG4FQ5lN

— This Week (@ThisWeekABC) December 18, 2020